.jpg?format=webp&width=780)
A study assessed adjuvant mitotane's efficacy in low to intermediate-risk patients. Results show a 5-year recurrence-free survival rate of 79% with mitotane and 75% with surveillance alone, with no significant overall survival difference. However, slow recruitment led to study discontinuation, preventing a conclusive stance on mitotane's efficacy. Adjuvant mitotane may not benefit low-risk, localized adrenocortical carcinoma patients, considering treatment-associated toxicity.
Like
Save
Share